We are live on
!
Find out more
Alphabet Inc Portfolio holdings
AUM
$99.1B
Turnover
13.79%
1-Year Est. Return
124.46%
This Fund
S&P 500
This Quarter
Est. Return
+16.04%
1 Year Est. Return
+124.46%
3 Year Est. Return
+326.82%
5 Year Est. Return
+231.24%
10 Year Est. Return
+1,201.66%
AUM
$4.02B
AUM Growth
+$1.44B
(+56%)
Cap. Flow
+$1.15B
Cap. Flow
% of AUM
28.6%
Top 10 Holdings %
Top 10 Hldgs %
94.04%
Holding
32
New
3
Increased
1
Reduced
3
Closed
6
Avg Time Held
3.5
years
Top 10 Avg Time Held
1.4
years
Top 20 Avg Time Held
1.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CME Group
CME
|
+$1.03B |
| 2 |
Planet Labs
PL
|
+$84.5M |
| 3 |
PayPay
PAYP
|
+$66.1M |
| 4 |
Ethos Technologies Inc
LIFE
|
+$44.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DexCom
DXCM
|
+$68.8M |
| 2 |
Revolution Medicines
RVMD
|
+$5.31M |
| 3 |
GeneDx Holdings
WGS
|
+$2.95M |
| 4 |
Exact Sciences
EXAS
|
+$2.36M |
| 5 |
Monte Rosa Therapeutics
GLUE
|
+$1.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 34.27% |
| 2 | Financials | 26.67% |
| 3 | Industrials | 24.53% |
| 4 | Healthcare | 14.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
CME Group
CME
$103B
| $1.03B | 25.63% |
+3,484,020
| New | +$1.03B |
2026 Q1
0 quarters
|
|
|
2
Planet Labs
PL
$5.14B
| $985M | 24.53% |
35,248,893
+3,306,252
| +10% | +$84.5M |
2021 Q4
17 quarters
|
|
3
AST SpaceMobile
ASTS
$12.6B
| $741M | 18.46% |
8,943,486
| – | – |
2025 Q1
4 quarters
|
|
|
4
Revolution Medicines
RVMD
$41.5B
| $320M | 7.97% |
3,292,525
-52,577
| -2% | -$5.31M |
2023 Q4
9 quarters
|
|
5
Arm
ARM
$254B
| $297M | 7.39% |
1,960,784
| – | – |
2023 Q3
10 quarters
|
|
6
Freshworks
FRSH
$3.57B
| $130M | 3.24% |
16,206,643
| – | – |
2021 Q4
17 quarters
|
|
7
UiPath
PATH
$6.81B
| $78.1M | 1.94% |
7,034,337
| – | – |
2021 Q2
19 quarters
|
|
8
Tempus AI
TEM
$12.4B
| $70.1M | 1.75% |
1,551,102
| – | – |
2024 Q2
7 quarters
|
|
|
9
PayPay
PAYP
$10.1B
| $66.7M | 1.66% |
+3,125,000
| New | +$66.1M |
2026 Q1
0 quarters
|
|
10
GitLab
GTLB
$8.86B
| $59M | 1.47% |
2,724,712
| – | – |
2022 Q2
15 quarters
|
|
11
Prime Medicine
PRME
$568M
| $57.6M | 1.44% |
16,562,498
| – | – |
2022 Q4
13 quarters
|
|
|
12
Ethos Technologies Inc
LIFE
$2.53B
| $42.1M | 1.05% |
+3,770,156
| New | +$44.6M |
2026 Q1
0 quarters
|
|
13
Maze Therapeutics
MAZE
$1.46B
| $41.4M | 1.03% |
1,388,583
| – | – |
2025 Q1
4 quarters
|
|
14
BridgeBio Oncology
BBOT
$233M
| $25.3M | 0.63% |
2,823,126
| – | – |
2025 Q3
2 quarters
|
|
15
Relay Therapeutics
RLAY
$3.74B
| $15.6M | 0.39% |
1,564,173
-4,580
| -0.3% | -$41K |
2020 Q3
22 quarters
|
|
|
16
Monte Rosa Therapeutics
GLUE
$839M
| $11.3M | 0.28% |
684,275
-60,673
| -8% | -$1.16M |
2021 Q2
19 quarters
|
|
17
Vera Therapeutics
VERA
$1.93B
| $9.71M | 0.24% |
241,264
| – | – |
2021 Q2
19 quarters
|
|
18
Sana Biotechnology
SANA
$698M
| $8.1M | 0.2% |
2,812,500
| – | – |
2021 Q1
20 quarters
|
|
19
Beam Therapeutics
BEAM
$2.44B
| $7.66M | 0.19% |
321,604
| – | – |
2020 Q1
24 quarters
|
|
20
Lyell Immunopharma
LYEL
$196M
| $5.88M | 0.15% |
293,256
| – | – |
2021 Q2
19 quarters
|
|
21
Oscar Health
OSCR
$10.6B
| $5.53M | 0.14% |
481,988
| – | – |
2021 Q1
20 quarters
|
|
22
Figma
FIG
$11.4B
| $4.56M | 0.11% |
215,582
| – | – |
2025 Q3
2 quarters
|
|
23
Spero Therapeutics
SPRO
$65.2M
| $2.08M | 0.05% |
889,979
| – | – |
2017 Q4
33 quarters
|
|
24
Hyperfine
HYPR
$84.8M
| $971K | 0.02% |
898,720
| – | – |
2021 Q4
17 quarters
|
|
25
Autolus Therapeutics
AUTL
$450M
| $964K | 0.02% |
698,262
| – | – |
2018 Q2
31 quarters
|
|
Similar funds
Alphabet Inc's Q1 2026 Portfolio in Review
As of Q1 2026, Alphabet Inc held 32 positions worth $4.02B, up 56% from $2.58B the previous quarter. Its ten largest holdings account for 94% of the portfolio.
Alphabet Inc deployed $1.15B of net new capital in Q1 2026, opening 3 new positions and adding to 1 existing holding. Its largest new stake was CME Group: 3,484,020 shares worth $1.03B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 50% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Revolution Medicines, an estimated $5.31M trimmed.
- Alphabet Inc's largest Q1 2026 buy was CME Group: 3,484,020 shares worth $1.03B.
- Alphabet Inc added most to Planet Labs in Q1 2026, an estimated $84.5M increase.
- Alphabet Inc's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $5.31M.
- Alphabet Inc fully exited DexCom in Q1 2026, selling an estimated $68.8M.
- Alphabet Inc's ten largest holdings make up 94% of its $4.02B portfolio in Q1 2026.
- Alphabet Inc opened 3 new positions and closed 6 in Q1 2026.
- Alphabet Inc's portfolio value rose 56% quarter-over-quarter to $4.02B.
Based on Alphabet Inc's 13F filing for Q1 2026, filed 8 May 2026.